PUNE, India, June 19, 2017 /PRNewswire/ --
According to a new market research report "Single-Cell Analysis Market by Product (Consumables and Instruments), Cell Type (Human and Animal), Technique (Flow Cytometry, NGS, PCR, and Mass Spectrometry), Application (Cancer, Neurology, NIPD, IVF, and CTCs), End User - Global Forecasts to 2022", published by MarketsandMarkets™, the market is expected to reach USD 3.59 Billion by 2022 from USD 1.67 Billion in 2017, at a CAGR of 16.5%.
Browse 107 market data tables and 42 figures spread through 175 pages and in-depth TOC on "Single-Cell Analysis Market"
Early buyers will receive 10% customization on reports
The growth in this market is mainly driven by the technological advancements in single-cell analysis products, increasing government funding for cell-based research, growing biotechnology and biopharmaceutical industries, wide applications of single-cell analysis in cancer research, growing focus on personalized medicine, and increasing incidence and prevalence of chronic and infectious diseases.
Consumables estimated to dominate the market in 2017
Based on the type of products, the Single-Cell Analysis Market is segmented into consumables and instruments. In 2017, the consumables segment is expected to dominate this market, primarily due to requirement of frequent and repeat purchase of these products as compared to instruments, which are considered as a one-time investment.
Download PDF Brochure: http://www.marketsandmarkets.com/pdfdownload.asp?id=171955254
Flow cytometry to have the largest market share in 2017
On the basis of technique, the Single-Cell Analysis Market is segmented into flow cytometry, NGS, PCR, microscopy, mass spectrometry, and other techniques (including single-molecule fluorescence in situ hybridization, micromanipulation, and automated capillary electrophoresis). In 2017, flow cytometry is expected to dominate the market. Wide usage of flow cytometry in single-cell analysis applications is expected to boost the demand for single-cell analysis techniques.
Talk To Our Research Analysts: http://www.marketsandmarkets.com/speaktoanalyst.asp?id=171955254
North America to dominate the market followed by Europe
On the basis of the region, the Single-Cell Analysis Market is segmented into North America, Europe, Asia, and RoW. In 2017, North America accounted for the largest share of the market, followed by Europe. The large share of the North American market is attributed to the factors such as increasing collaborations among prominent players, technological advancements, and expanding biotechnology and pharmaceutical industries. Factors such as increasing incidence of diseases, government support for various research activities, and growing focus on stem cell research and regenerative medicine are expected to fuel the market growth in the European region.
The Single-Cell Analysis Market is highly competitive with the presence of major players. Merck KGaA (Germany), Becton, Dickinson and Company (U.S.), Promega Corporation (U.S.), Danaher Corporation (U.S.), General Electric Company (U.K.), Thermo Fisher Scientific Inc. (U.S.), Miltenyi Biotec (Germany), Illumina, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Fluidigm Corporation (U.S.), NanoString Technologies, Inc. (U.S.), Agilent Technologies (U.S.), Abcam Plc (U.S.), NuGEN Technologies, Inc. (U.S.), LumaCyte (U.S.), PluriSelect Life Science UG & Co. KG (Germany), Sysmex Partec (U.S.), Bio-Techne Corporation (U.S.), Promega Corporation (U.S.), 10x Genomics (U.S.), WaferGen Bio-systems, Inc. (U.S.), Bruker (U.S.), and Fluxion Biosciences (U.S.) are companies operating in the Single-Cell Analysis Market.
Browse Related Reports:
Cell Signaling Market by Type (Endocrine, Paracrine), Pathway (Akt, AMPK, Hedgehog, Notch), Product (Consumables, Instruments), Technology (Flow Cytometry, ELISA, Mass Spectrometry) & Application (Research, Cancer, Immunology) - Global Forecast to 2022
NGS-based RNA-seq Market by Products & Services (Sample Preparation, Consumables, Bioinformatics), Technology (SBS, SMRT), Application (De novo, Transcriptome Epigenetics, Small RNA), End User (Research Centers, BioPharma Companies) - Global Forecast to 2022
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets's flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
701 Pike Street
Suite 2175, Seattle,
WA 98101, United States
Visit Our Blog@ http://mnmblog.org/market-research/healthcare/biotechnology
Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets